Categories: CauseDrugHealthTechMedtech
Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.10.2024 | Series A | $2.35M | - |
Mentions in press and media 3
| Date | Title | Description |
| 30.10.2024 | TXN Systems Raises SEK25M in Series A Funding | TXN Systems, a Solna, Sweden-based pharmaceutical company developing a first-in-class antibiotic for multidrug-resistant urinary tract infections, raised SEK25M in Series A Funding.
Backers included Mikael Lönn, MD and Jens Mogensen, alongs... |
| 30.10.2024 | TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic | TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic
Wed, Oct 30, 2024 12:30 CET Report this content
EbsArgent targets urinary tract infections, with early indications of efficacy against many species of multidrug... |
| - | Thioredoxin Systems | “Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The” |
Reviews 0
